Dosiseskaleringsundersøgelse af CLR 131 hos børn, unge og unge voksne med recidiverende eller refraktære maligne tumorer, herunder men ikke begrænset til neuroblastom, rhabdomyosarkom, Ewings sarkom og osteosarkom (CLOVER-2)
En åben-label, dosiseskalering, effektivitet og sikkerhedsundersøgelse af CLR 131 hos børn, unge og unge voksne med udvalgte solide tumorer, lymfom og ondartede hjernetumorer
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Even with standard, highly toxic multimodality therapies and salvage regimen, most pediatric patients with primary metastatic or relapsed solid tumors are confronted with a poor prognosis. For these patients there is currently no accepted successful treatment regimen. There is a need for new drugs, including targeted radiopharmaceuticals, preferably with cancer-specific uptake and broad applicability for these rare pediatric malignancies.
CLR 131 is a radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound (CLR1404) is radiolabeled with the isotope iodine-131 (I-131). CLR 131 has demonstrated tumor selective uptake across numerous adult and pediatric cancer cell types. Therapeutic efficacy has been demonstrated in various pediatric and adult-type cancer xenograft models, confirming the ability of CLR 131 to target tumors.
Based on the critical unmet medical need for effective agents with novel mechanisms of action in relapsed pediatric cancers and initial preclinical and clinical experience with radioiodinated CLR1404, Cellectar Biosciences has chosen to assess CLR 131 in a phase 1 pediatric trial.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Westmead, New South Wales, Australien, 2145
- Children's Hospital at Westmead
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X8
- Hospital for Sick Children
-
-
-
-
California
-
Palo Alto, California, Forenede Stater, 94304
- Lucile Packard Children's Hospital
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27708
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Texas Children's Hospital
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- University of Wisconsin Hospital and Clinics
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
All Patients
- Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or radiographically suspected to be relapsed, refractory, or recurrent for which there are no standard treatment options with curative potential. Note: patients with diffuse intrinsic pontine glioma (DIPG) may enroll without histological or cytological confirmation.
- ≥ 2 years of age and ≤ 25 years of age at time of consent/assent
- If ≥ age 16 years, Karnofsky performance status of ≥ 60. If < age 16 years, Lansky performance status ≥ 60
- Platelets ≥ 75,000/µL (last transfusion, if any, must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Absolute neutrophil count ≥ 750/µL
- Hemoglobin ≥ 8 g/dL (last transfusion must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Using the bedside Schwartz formula, estimated GFR (creatinine clearance) > 60 ml/min/1.73m2
- Alanine aminotransferase < 3 × ULN
- Bilirubin < 2 × ULN
- Patients who have undergone autologous or allogeneic bone marrow transplant must be at least 3 months from transplant.
- Patients enrolling at total dose levels > 30 millicurie (mCi)/m2 must have availability or ability to collect an autologous hematopoietic stem cell back-up product prior to CLR 131 administration. At minimum, 2 x 10^6/kg cryopreserved CD34+ cells must be available.
- Patient or his or her legal representative is judged by the Investigator to have the initiative and means to be compliant with the protocol.
Patients with Pediatric Solid Tumor or Lymphoma
- At least 1 measurable lesion with longest diameter of at least 10 mm. Patients with a lesion(s) that are determined to be Metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) positive may be enrolled at the investigator's discretion, even if not associated with a measurable lesion of at least 10 mm. Patients with neuroblastoma who have detectable disease may enroll provided they meet the requirements of the International Neuroblastoma Response Criteria.
- Patients with known brain metastases must have completed any radiotherapy or systemic treatments for brain metastases prior to enrollment; by investigator assessment be considered stable with no new signs or symptoms for at least 1 month, and on a stable dose of steroids (unchanged for three weeks prior to registration or on a steroid tapering regimen).
Patients with Recurrent or Refractory Brain Tumors
- At least 1 measurable lesion with longest diameter of at least 10 mm on any imaging sequence.
- Patients with previously known neurological deficits must be clinically stable at time of enrollment and able to complete all study related procedures. Patients with documented or newly diagnosed neurological deficits will be enrolled at the investigator's discretion.
- If patient receives steroids for neurological symptom control, the dose must be stable (unchanged for three weeks prior to registration) or on a steroid tapering regimen. Initiation of steroids per routine care immediately prior to CLR 131 dosing is acceptable.
Exclusion Criteria:
- Patients receiving active treatment for central nervous system metastases or those that are likely to require active treatment during anticipated participation in this trial. Patients with stable brain metastases treated with steroids may enroll at the investigator's discretion
- For solid tumor and lymphoma patients only, central nervous system involvement unless previously treated with surgery, systemic therapy, or radiotherapy with the patient neurologically stable. Patients with metastatic brain tumors that have been previously treated are allowed, provided the patient is neurologically stable (determined at the investigator's discretion).
- Antitumor therapy or investigational therapy, within 2 weeks of dosing. For certain types of radiation (craniospinal, total abdominal, whole lung [spot irradiation to skull-based metastases is not considered craniospinal radiation for the purposes of this study]), at least 3 months must have elapsed. No washout is required for palliative focal radiation. NOTE: Patients participating in non-interventional clinical trials (i.e., non-drug) are allowed to participate in this trial
- Patients previously treated with iodine-131 (131I)-MIBG who have already received a cumulative I-131 dose > 54 mCi/kg or who would exceed 54 mCi/kg by participating in this trial, are not eligible.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: CLR 131
CLR 131 intravenous administration |
IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with dose limiting toxicities (DLT)
Tidsramme: up to 64 days
|
DLT will be assessed by physical examination, vital signs, and laboratory values |
up to 64 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Identification of recommended phase 2 dose of CLR 131 in children, adolescents, and young adults
Tidsramme: until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
Dose and regimen to be used in Phase 2 trials of CLR 131 in children, adolescents, and young adults |
until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
|
Determination of preliminary antitumor activity of CLR 131 in children, adolescents, and young adults
Tidsramme: through Day 85
|
Response assessment per applicable criteria (e.g., Neuroblastoma Response Criteria (modified); RECIST 1.1; positron emission tomography response criteria in solid tumors (PERCIST); RANO) |
through Day 85
|
|
Determination of therapeutic activity of CLR 131 in children, adolescents, and young adults
Tidsramme: up to 22 days post initial infusion
|
Assessment via 131-I/CLR 131 SPECT/CT scans |
up to 22 days post initial infusion
|
|
Determination of event free survival following CLR 131 infusion in children, adolescents, and young adults
Tidsramme: 1 month to 5 years
|
Time from first infusion of CLR 131 until progression or recurrence of disease |
1 month to 5 years
|
|
Determination of overall survival following CLR 131 infusion in children, adolescents, and young adults
Tidsramme: 1 month to 5 years
|
Time from first infusion of CLR 131 until death due to any reason |
1 month to 5 years
|
|
Determine dosimetry of CLR 131 in children, adolescents, and young adults
Tidsramme: up to 15 days post initial infusion
|
Assessment of dosimetry via whole body planar imaging |
up to 15 days post initial infusion
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Jarrod Longcor, Cellectar Biosciences
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- lymfom
- osteosarkom
- Ewing sarkom
- ATRT
- glioblastom
- Non-Hodgkin lymfom
- neuroblastom
- medulloblastom
- højgradigt gliom
- rhabdomyosarkom
- DIPG
- sarkom
- Wilms tumor
- ependymom
- PNET
- gliosarkom
- sjælden kræft
- Hodgkin lymfom
- desmoplastisk små rundcellet tumor
- ondartet kimcelletumor
- synovialt sarkom
- DSRCT
- diffust-intrinsisk pontine gliom
- atypisk teratoid rhabdoid tumor
- primitiv neuroektodermal tumor
- gliomatosis cerebri
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Genetiske sygdomme, medfødte
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Urologiske neoplasmer
- Astrocytom
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Neoplasmer i nervesystemet
- Nyre-neoplasmer
- Neoplastiske syndromer, arvelig
- Neoplasmer, bindevæv og blødt væv
- Neuroektodermale tumorer, primitive, perifere
- Neoplasmer, Knoglevæv
- Neoplasmer, bindevæv
- Neoplasmer i centralnervesystemet
- Neoplasmer, muskelvæv
- Neoplasmer, komplekse og blandede
- Myosarkom
- Neoplasmer i hjernen
- Neoplasmer i hjernestammen
- Infratentoriale neoplasmer
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Hemiske og lymfatiske sygdomme
- Diffus Intrinsic Pontine Gliom
- Lymfom
- Glioblastom
- Gliom
- Neuroblastom
- Sarkom, Ewing
- Lymfom, Non-Hodgkin
- Sarkom
- Hodgkins sygdom
- Sarkom, synovial
- Rhabdomyosarkom
- Gliosarkom
- Osteosarkom
- Ependymom
- Medulloblastom
- Neuroektodermale tumorer, primitive
- Wilms Tumor
- Rhabdoid tumor
- Desmoplastisk lille rundcellet tumor
- Neoplasmer, Neuroepithelial
- CLR1404
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- DCL-17-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .